As of 2026-09-19, the EV/EBITDA ratio of Arrowhead Pharmaceuticals Inc (ARWR) is -59.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARWR's latest enterprise value is 10,570.30 mil USD. ARWR's TTM EBITDA according to its financial statements is -177.03 mil USD. Dividing these 2 quantities gives us the above ARWR EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 16.1x | 15.0x |
| Forward P/E multiples | 13.9x - 16.6x | 15.0x |
| Fair Price | (24.57) - 230.84 | 90.31 |
| Upside | -137.0% - 247.2% | 35.8% |
| Date | EV/EBITDA |
| 2026-09-17 | -60.71 |
| 2026-09-16 | -59.16 |
| 2026-09-15 | -63.04 |
| 2026-09-14 | -71.00 |
| 2026-09-11 | -72.74 |
| 2026-09-10 | -72.66 |
| 2026-09-09 | -72.56 |
| 2026-09-08 | -74.53 |
| 2026-09-04 | -75.51 |
| 2026-09-03 | -75.63 |
| 2026-09-02 | -74.74 |
| 2026-09-01 | -72.65 |
| 2026-08-31 | -72.37 |
| 2026-08-28 | -74.38 |
| 2026-08-27 | -77.30 |
| 2026-08-26 | -77.73 |
| 2026-08-25 | -77.53 |
| 2026-08-24 | -75.82 |
| 2026-08-21 | -76.13 |
| 2026-08-20 | -76.41 |
| 2026-08-19 | -77.96 |
| 2026-08-18 | -76.75 |
| 2026-08-17 | -77.39 |
| 2026-08-14 | -75.75 |
| 2026-08-13 | -74.92 |
| 2026-08-12 | -76.24 |
| 2026-08-11 | -77.82 |
| 2026-08-10 | -77.10 |
| 2026-08-07 | -76.56 |
| 2026-08-06 | -75.11 |
| 2026-08-05 | -75.97 |
| 2026-08-04 | -78.10 |
| 2026-08-03 | -75.25 |
| 2026-07-31 | -74.17 |
| 2026-07-30 | -76.29 |
| 2026-07-29 | -75.42 |
| 2026-07-28 | -75.07 |
| 2026-07-27 | -74.87 |
| 2026-07-24 | -74.92 |
| 2026-07-23 | -75.86 |
| 2026-07-22 | -77.39 |
| 2026-07-21 | -66.11 |
| 2026-07-20 | -63.82 |
| 2026-07-17 | -65.93 |
| 2026-07-16 | -63.61 |
| 2026-07-15 | -63.96 |
| 2026-07-14 | -64.03 |
| 2026-07-13 | -65.78 |
| 2026-07-10 | -67.60 |
| 2026-07-09 | -73.65 |